Efranat Ltd develops a unique anti-cancer immunotherapy treatment based on a natural plasma protein molecule.

The concept underlying the technology is to engage the body's own immune system and harness it against cancer. 

Efranat's product is a very potent immunomodulator that activates macrophages, a group of white blood cells that play key role in the innate immune system’s defense against cancer.  

The product is manufactured and processed under GMP in a procedure that mimics the natural process in the body .

Treatment of dogs with spontaneous tumors shows promising results.

Efranat is currently conducting human Phase 1 clinical trial in cancer patients with advanced solid tumors at Sheba hospital. 

GMP Production 

Efranat's product was manufactured under  cGMP at Kamada Ltd.Kamada, founded in 1990, is a biopharmaceutical company engaged in developing, producing and marketing specialty life-saving therapeutics.
Kamada specializes in protein purification technology from human plasma, using unique methods

Learn more

Phase 1 study 

Efranat is currently conducting a Phase 1 study at "Sheba" hospital. This study is open label, dose-escalation trial aiming to evaluate the safety and tolerability of Efranat's product in subjects with advanced solid malignancies. Study population will consist of up to 48 male or female participants, ages 18-80, diagnosed with inoperable, recurrent or metastatic malignant solid tumors, deemed incurable, and who have failed to respond to standard therapy or for whom no standard therapy is available.For more details about the Clinical trial click here

News & Events

News & Events
  • Nov 2015

    Dr Talia Golan - Sheba hospital at AACR

    read more
  • Oct 2015

    Second expanded cohort of Phase I study

    read more
  • Sept 2015

    Dr. Rinat Rotem joined Efranat

    read more
  • Aug 2015

    Efranat's product name was changed

    read more
  • June 2015

    Phase I Dose Escalation completion

    read more